HISCO: fat emulsion amino acid (17) glucose (11%) injection passed the consistency evaluation of generic drugs

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Tianjin Port Launches New Route to South America's East Coast

May 6th, a new sea route was opened in Tianjin, connecting China to the east coast of South America. The aim is to boost trade between China and countries in the region while enhancing transportation capacity. Crossing the Pacific Ocean, the sea route between China and South America is one of the longest globally. Experts suggest that this new route will facilitate commercial and trade cooperation between China and South America.

Chinese Exports Rebound, Container Shortage on China-South America Route

EqualOcean has learned that the demand in the shipping market from China to South America has surged suddenly after the May Day holiday.

The 10th China-LAC Infrastructure Cooperation Forum to held in Macao

May 10th, the organizing committee of the International Infrastructure Investment and Construction Forum held a press conference in Beijing, announcing that the 15th International Infrastructure Forum will be held in Macau from June 19th to 21st, concurrently with the 10th China-LAC Infrastructure Cooperation Forum organized by the Ministry of Commerce of China.

China's Leading Domestic HMO Enterprise Synaura Completes First Round of Financing

EqualOcean has learned that Synaura(虹摹生物)recently successfully completed a pre-Series A financing round of nearly CNY 100 million. This round of financing was led by Zhongjin Capital's CICC Qide Fund(中金启德基金) and followed by Maotai Investment(茅台基金). The new funds will be used for new product research and development, laboratory construction, industrialization, and commercial promotion, injecting new momentum into Synaura's innovative development in the HMO field.